Reduced side-effect hemoglobin compositions

US6670323B1 · kind B1 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH

Inventors

• Douglas L. Looker · Lafayette, US
• Izydor Z. Apostol · Boulder, US
• Eric A. Brucker · Evergreen, US
• Michael P. Doyle · Peachtree City, US
• David L. Foster · Watertown, US
• Christopher B. Glascock · Louisville, US
• James C. Hartman · Boulder, US
• Geoffrey F. Lee · Pacifica, US
• Douglas D. Lemon · Louisville, US
• Edwin G. Moore · Libertyville, US
• Jane P. Richards · Longmont, US
• Michael R. Schick · Louisville, US
• Stephen P. Trimble · Boulder, US
• David E. Pereira · Apex, US
• Ton That Hai · Round Lake, US
• Kenneth E. Burhop · Fallbrook, US

Key dates

• Filing date: Nov 10, 2000
• Grant date: Dec 30, 2003
• Expiry date: Aug 3, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.